Original Research Article

The impact of insulin resistance, dyslipidemia and high sensitivity C-reactivity protein on carotid intima-media thickness in metabolic syndrome

Sangeeta M. Gawali1*, Mahesh S. Karandikar2

1Department of Physiology, B.J. Government Medical College, Pune, Maharashtra, India
2Department of Physiology, Dr. D.Y. Patil Medical College, Pune, Maharashtra, India

Received: 03 June 2021
Accepted: 03 July 2021

*Correspondence:
Dr. Sangeeta M. Gawali,
E-mail: sangeetagawali123@yahoo.com

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Background: Carotid intima-media thickness (CIMT) is a strong predictor of cardiovascular events and associated with metabolic syndrome (MetS). The CIMT has been widely used as one of the parameters of atherosclerosis. The aim of the study was to evaluate the impact of insulin resistance, dyslipidemia and high sensitivity C-reactive protein on carotid intima-media thickness in metabolic syndrome patients of Western Maharashtra as very sparse data is available.

Methods: It was a cross-sectional study of 400 adults (200 cases and 200 control), 18-50 years of age, both the sexes randomly selected from diabetes and obesity OPD at tertiary care hospital. Diagnosis of metabolic syndrome was done according to modified NCEP adult treatment panel III criteria. CIMT was measured by B mode ultrasound (Philips HT-11, Color Doppler), hs-CRP by ELISA method (Cal biotech). Insulin resistance by HOMA-IR (Homeostatic model assessment of insulin resistance). The predictors of CIMT with various variables were studied by multiple linear regression analysis.

Results: We found significant increase in CIMT (0.7895±0.110, p<0.001) in MetS and a positive correlation of CIMT with age, waist to hip ratio, triglyceride levels and systolic blood pressure (p<0.001).

Conclusions: Increased carotid intima-media thickness in metabolic syndrome may increase the risk of having a stroke and cardiovascular mortality. It was considered an early deterioration in the arterial intima and is a preclinical stage of atherosclerosis. Early diagnosis and prevention may help to reduce the risk of stroke and cardiovascular mortality.

Keywords: Metabolic syndrome, Insulin resistance, Cardiovascular risk markers, CIMT, hs-CRP

INTRODUCTION

The metabolic syndrome (syndrome X, insulin resistance syndrome) consists of a constellation of metabolic abnormalities that confer an increased risk of cardiovascular disease (CVD) and diabetes mellitus. Individuals with the metabolic syndrome are twice as likely to die of cardiovascular disease as those who do not and their risk of acute myocardial infarction or stroke is three-fold higher.1 The approximate prevalence of metabolic syndrome among patients with coronary heart disease (CHD) is 50%, with a prevalence of ~35% among patients with premature coronary artery disease (before or at age 45 years).1 Obesity is the driving force behind metabolic syndrome. Data also indicate that atherogenic dyslipidemia, glucose intolerance, thrombotic tendency, subclinical inflammation, and endothelial dysfunction are proportionately higher in metabolic syndrome.2,3 Atherogenic dyslipidemia is an integral component of metabolic syndrome and is a major contributor to cardiovascular risk in these patients. Carotid intima-media thickness (CIMT) is a marker of atherosclerosis development and predictor of cardiovascular events in daily clinical practice.
It alerts physicians to any thickening when patients are still asymptomatic. Early detection may indicate the need for a more aggressive approach to managing the risk factors associated with heart disease and stroke. There has been an increasing interest in the involvement of low-grade inflammation in the pathogenesis of metabolic syndrome. Recently hs-CRP has received the most attention as a marker of inflammation in metabolic syndrome responsible for cardiovascular diseases. For more than 30 years, cardiovascular risk prediction algorithms have relied on blood pressure, smoking status, hyperlipidemia, and the presence or absence of diabetes. The time has come for careful consideration of adding CIMT as an atherosclerosis index as a clinical criterion for metabolic syndrome. The aim of the study was to evaluate the CIMT in metabolic syndrome patients and to assess its correlation with insulin resistance, hs-CRP and dyslipidemia.

**METHODS**

**Study design**

This was a cross-sectional analytic study.

**Study type**

The study type was comparative and correlation study.

**Study period**

The study period was December 2018 to May 2020.

**Sample size**

Sample size was calculated by using WinPepi software. Assuming an increase in CIMT of 7 mm with a standard deviation 0.35, it was estimated to be 200 participants in each group would provide 90% power at an α-level of 0.05.

**Participants**

200 diagnosed cases of metabolic syndrome attending diabetes and obesity OPD in the age group of 18 to 50 (100 males and 100 females) were studied and compared with 200 age and sex-matched control group (100 males and 100 females).

**Source**

The study was conducted in the physiology department in collaboration with medicine (obesity, diabetes) OPD, CCL- biochemistry, radiology and microbiology serology laboratory of tertiary care hospital of western Maharashtra.

**Ethical approval**

Institutional ethical committee approval was obtained before the start of the study and informed consent was taken from all subjects.

**Inclusion criteria**

Diagnosis of metabolic syndrome was done according to modified NCEP National Cholesterol Education Program, Adult Treatment Panel III criteria (2004). The individuals who meet at least three of the five clinical criteria were included. Central obesity- waist circumference >90 cm in men and >80 cm in female, BSL >100 mg/dl or T2DM or specific medication, BP >130/85 mmHg or specific medication, triglycerides >150 mg/dl or specific medication, HDL <40 mg/dl in men <50 in women.

**Exclusion criteria**

Non-obese and obese patients that do not meet criteria for metabolic syndrome, acute infections, chronic infections like rheumatoid arthritis, autoimmune disorders, patients with a previous history of coronary artery disease, hepatic and kidney disease, malignancy, chronic obstructive pulmonary disease and endocrinological disorder like hypothyroidism, PCOS, acromegaly, Cushing syndrome.

**Data collection**

Demographic, socioeconomic, and self-reported behavioral information (smoking, alcohol, physical activity, and diet), objective measures of anthropometry (height, weight, BMI, waist circumferences, waist to hip ratio) and vital parameters heart rate, blood pressure and thorough clinical examination was done.

**Biochemical parameters**

**Blood sugar**

Fasting, postprandial glucose by using glucose GOD-PAP method (Biolab diagnostics) was done.

**Lipid profile**

Triglycerides- GPO-PAP method (Pathozyme diagnostics) and HDL- direct method (Pathozyme diagnostics) was done.

**Insulin**

Fasting by electro-chemiluminescence immune assay, ECLIA-Roche (Cobas kit).

**High sensitivity C-reactive proteins (hs-CRP)**

By enzyme-linked immunosorbent assay- ELISA method (Cal biotech) was done.

**Insulin resistance**

By HOMA-IR, for estimation of insulin sensitivity. Way to reveal the dynamic between your baseline (fasting) blood sugar and the responsive hormone insulin.
**Carotid intima-media thickness test**

CIMT by B mode ultrasound (Philips HT-11, Color Doppler).

The test measures the thickness of the inner two layers of the carotid artery, the intima, and media at the internal carotid artery. CIMT above 1.0 mm is regarded as abnormal and above 1.2 mm considered high risk.

**Procedure**

The ultrasound probe is placed on the skin overlying carotid arteries in the neck. The technique used to measure and calculate CIMT was to measure a double line with the definition of the light-intima and media-adventitia interfaces of the vessel. The distance between the two acoustic interfaces was considered the CIMT measure. The intima-media thickness IMT was defined as the distance between the leading edges of the 2 echogenic lines separated by a hypo echogenic space; the first line represented luminal-intimal transition and the second medial-adventitial. Three determinations of IMT were conducted at the site of the thickest and two adjacent points (1 cm up and downstream from the thickest point) and were averaged (mean IMT).

**Statistical analysis**

Statistical Package for Social Science (SPSS) program version 15 was used for the analysis of data. Data were presented as mean±SD. Pearson correlation coefficient was used for detection of the correlation between HOMA-IR and CIMT variables. P value<0.05 was considered significant. The multiple linear regression analysis was done to reveal a predictive model of CIMT.

**RESULTS**

This was a cross-sectional analytic, tertiary care hospital-based study on 200 metabolic syndrome patients attending obesity and diabetic OPD with an equal number of age and sex-matched controls. 200 out of these, there were 100 males and 100 females in each group. The mean age in both groups was 42.5±0.49 with an age range from 18 to 50 years. All subjects were evaluated for components of metabolic syndrome, adiposity markers, insulin resistance and atherosclerotic markers like hs-CRP and carotid intima-media thickness. The weight and adiposity parameters like BMI (26.89±0.4089), WC (103.3±14.9), and WHR (0.96±0.0057) were significantly (p<0.0001) higher in metabolic syndrome patients as compared to BMI (22.59±0.2611), WC (70.57±7.6), and WHR (0.96±0.0057) control group (Table 1).

The individual components of MetS were significantly higher and low HDL levels were found in MetS patients when compared with control (p<0.0001). Fasting blood sugar (158.2±9.97 vs 96.94±0.97), systolic blood pressure (135±9.3 vs 114.9±0.63), diastolic blood pressure (86.61±0.69 vs 74.52±0.42), triglycerides (160.7±1.41 vs 105.1±1.15) and HDL (38.05±0.44 vs 50.88±0.45). High insulin resistance HOMA-IR (6.836±0.086 vs 1.36±0.0412) and high levels of fasting insulin (18.24±0.258 vs 5.836±0.1745), <0.001 were found in MetS (Table 1). Atherosclerotic markers like hs-CRP (5.5±0.9881), triglyceride were significantly higher (p<0.0001) and low HDL levels were found in MetS as compared to controls (0.65±0.4927) (Table 1).

Carotid intimal thickness was higher in MetS as compared to control. CIMT right side-0.7854±0.1082 vs 0.4251±0.082 (p<0.0001) and CIMT left side-0.7937±0.109 vs 0.4292±0.085 (p<0.0001). Left-sided carotid artery thickness was found greater than the right side. There was no significant correlation of CIMT with insulin resistance and hs-CRP (p>0.05) but there is a positive association with lipids.

An increase in CIMT is not associated with insulin resistance (Table 2). The multiple linear regression analysis revealed a predictive model, the predictors of left-sided CIMT are age, WHR, hs-CRP, triglyceride, HDL and systolic blood pressure (Figure 1). It revealed systolic blood pressure as a significant predictor of left-sided CIMT (Table 3). The predictors of right-sided CIMT are age, WHR, hs-CRP, triglyceride, HDL, fasting insulin (Figure 2) (Table 4).

**Table 1: Demographic, clinical and metabolic characteristics of patients with metabolic syndrome (N=200) and healthy controls (N=200).**

| Parameters   | Control (mean±SD) | Case (mean±SD) | P value |
|--------------|------------------|----------------|---------|
| Age (years)  | 41.5±0.56        | 42.5±0.49      | p>0.05  |
| BMI          | 22.59±0.2611     | 26.89±0.4089   | p<0.0001|
| Waist circumferen| 70.57±17.6     | 103.3±14.9     | p<0.0001|
| WHR          | 0.79±0.0049      | 0.96±0.0057    | p<0.0001|
| Systolic BP  | 114.9±0.63       | 135±0.93       | p<0.0001|
| Diastolic BP | 74.52±0.42       | 86.61±0.69     | p<0.0001|
| Heart rate   | 82.91±8.46       | 114.6±9.12     | p<0.0001|
| Fasting sugar| 96.94±0.97       | 158.2±2.92     | p<0.0001|
| PP sugar     | 119.2±1.46       | 236.6±54       | p<0.0001|
| Triglyceride | 105.1±1.15       | 160.7±1.41     | p<0.0001|

Continued.
### Table 2: Pearson correlation coefficient between CIMT with HOMA-IR, hs-CRP and lipid levels.

| Correlation coefficient | R value | P value |
|-------------------------|---------|---------|
| hs-CRP                  | 0.24    | p>0.05  |
| HOMA-IR                 | 0.13    | p>0.05  |
| Triglycerides           | 0.37    | p<0.001 |
| HDL                     | 0.30    | p<0.001 |

Note: p<0.05 significant, p<0.001 highly significant.

### Table 3: Multiple linear regression analysis of CIMT-LT with all variables.

| Variables     | F       | R2      | P value |
|---------------|---------|---------|---------|
| Age (years)   | 5.43    | 0.0267  | p<0.05  |
| hs-CRP        | 15.8    | 0.074   | p<0.001 |
| HOMA-IR       | 0.122   | 0.0006  | p<0.05  |
| F insulin     | 2.84    | 0.014   | p<0.05  |
| Triglyceride  | 23.72   | 0.107   | p<0.001 |
| HDL           | 16.39   | 0.76    | p<0.0001|
| SBP           | 4.28    | 0.021   | p<0.05  |
| DBP           | 0.45    | 0.0022  | p<0.05  |
| AC            | 1.60    | 0.008   | p<0.05  |
| WHR           | 5.34    | 0.026   | p<0.05  |

### Table 4: Multiple linear regression analysis of CIMT-RT with all variables.

| Variables     | F       | R2      | P value |
|---------------|---------|---------|---------|
| Age           | 5.7     | 0.02    | p<0.05  |
| hs-CRP        | 9.4     | 0.04    | p<0.05  |
| HOMA-IR       | 0.0006  | 0.000033| p<0.05  |
| F insulin     | 4.36    | 0.021   | p<0.05  |
| Triglycerides | 23.6    | 0.1069  | p<0.05  |
| HDL           | 16.72   | 0.077   | p<0.05  |
| SBP           | 5.6     | 0.02    | p<0.05  |
| DBP           | 0.28    | 0.0014  | p<0.05  |
| AC            | 1.2     | 0.0060  | p<0.05  |
| WHR           | 6.3     | 0.03    | p<0.05  |

Figure 1: Multiple linear regression analysis of CIMT-LT with all variables.
DISCUSSION

There was a growing body of evidence that among risk factors that promote atherosclerosis, metabolic syndrome is a powerful and prevalent predictor of cardiovascular events. The systemic inflammatory process associated with metabolic syndrome has numerous deleterious effects that promote plaque activation, which is responsible for clinical events. Interactions between the innate immune system with lipid-derived products seem to play a major role in the pathophysiology of atherosclerosis about the metabolic syndrome.

Increase carotid intima-media thickness was considered an early deterioration in the arterial intima and is a preclinical stage of atherosclerosis. Despite controversial results, the majority of studies have recommended measuring CIMT in clinical practice for the assessment of cardiovascular risk. Carotid intima-media thickness is an index of atherosclerosis in the vascular bed and is highly predictive of the development of atherosclerosis; incident metabolic syndrome provides additional information regarding the progression of preclinical atherosclerosis beyond conventional risk factors and can therefore improve the prediction of clinical CVD. In this study, among the various components of metabolic syndrome triglycerides and HDL levels have shown a positive correlation with CIMT.

CIMT measures the thickness of the 2 innermost layers (intima and media) of the walls of the carotid arteries (located within the neck). These layers tend to get thicker with dyslipidemia. Abnormal thickening of the artery wall is the first sign of plaque formation. Clinical studies over the previous few decades have shown that after factoring for age, gender, and ethnicity, individuals with increased CIMT values have a greater risk of coronary failure and stroke than those with CIMT values that are judged to be normal for the comparable group. There was no correlation between hs-CRP and CIMT in this study.

The measurement of markers of inflammation has been proposed as a method to improve global cardiovascular risk prediction. hs-CRP serves as a marker of inflammation and predicts the risk of adverse cardiovascular events. Moreover, chronic subclinical inflammation was associated with cardiovascular risk and a significant linear increase in CIMT with increasing quartiles of hs-CRP.

When determined with a high sensitivity test, hs-CRP is an independent predictor of future cardiovascular events and adds prognostic information to lipid screening. After having analyzed the results of the 200 MetS, we found that the combination of MetS components affects CIMT. Amongst the components of MetS, the factors that had the strongest associations with CIMT were arterial hypertension and lipid levels.

We did not find any relation between CIMT and HOMA-IR. Insulin resistance does not affect increased CIMT. It was necessary to spot the relevant risk factors for CIMT to facilitate the first comprehensive prevention and treatment of macroangiopathy. According to previous studies, CIMT can be affected by many factors, including age, sex, smoking, blood pressure, blood lipid levels, thyroid function, blood glucose levels, blood glucose level fluctuations, and C-peptide levels. The present results support the findings of studies in middle-aged individuals that have reported an instantaneous relationship of metabolic risk factors.

Bilateral CIMTs became thicker with age (p<0.001). In addition to this, the left CIMT in Figure 1 was thicker than the right Figure 2 and associate positively with systolic blood pressure in this study. Of the components, increased waist to hip ratio and triglyceride levels contribute to the association between metabolic syndrome and the change in carotid IMT. These data suggest that emphasis should be focused on multiple metabolic risk factors rather than on each risk factor separately. With this approach, it would be possible to identify a large number of individuals who are at an increased risk for clinical CVD.

Limitations

The limitations of the study were that CHD prediction by ultrasonography-assessed carotid plaque may be more representative of atherosclerosis than CIMT. So,
measurement of carotid plaque would have added more value for the assessment of cardiovascular risk factors in metabolic syndrome.

CONCLUSION

Increased CIMT is associated with age, dyslipidemia, high waist to hip ratio, raised systolic blood pressure. Increased CIMT is a worthwhile predictor of subsequent CHD and stroke, the two leading causes of cardiovascular death. CIMT may provide additional prognostic information to that of conventional risk factors is pivotal in discussing its clinical utility in primary prevention.

Recommendations

Authors recommend evaluation of CIMT in metabolic syndrome patients as a routine test to get an insight into vascular changes associated with age, hypertension and dyslipidemia.

ACKNOWLEDGEMENTS

We would like to thank medicine, biochemistry, radiology and microbiology departments for their valuable help.

Funding: No funding sources  
Conflict of interest: None declared

Ethical approval: The study was approved by the Institutional Ethics Committee

REFERENCES

1. Eckel RH. Metabolic syndrome. Harrison’s principle of the internal medicine. 19th ed. New York, NY: McGraw Hill; 2015: 2449.
2. Rao GHR, Thanickachalam S. Coronary Artery Disease: Risk Promoters, Pathophysiology, and Prevention. 1st ed. New Delhi: South Asian Society on Atherosclerosis and Thrombosis; 2005.
3. Mohan V, Rao GHR. Type 2 Diabetes in South Asians. 1 st ed. New Delhi: South Asian Society on Atherosclerosis and Thrombosis; 2007.
4. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288(21):2709-16.
5. Neill AM, Rosamond WD, Girman CJ, Heiss G, Golden SH, Duncan BB, et al. Prevalence of coronary heart disease and carotid arterial thickening in patients with the metabolic syndrome (The ARIC Study). Am J Cardiol. 2004;94(10):1249-54.
6. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Bonadonna RC, et al. Carotid atherosclerosis and coronary heart disease in the metabolic syndrome: prospective data from the Bruneck study. Diabetes Care. 2003;26(4):1251-7.
7. Frostegard J. Immunity, atherosclerosis, and cardiovascular disease. BMC Med. 2013;11:117.
8. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation. 2007;115:459-67.
9. Novo S, Peritore A, Trovato RL, Guarnieri FP, Lisi D, Muratori I, et al. Preclinical atherosclerosis and metabolic syndrome increase cardiovascular and cerebrovascular events rate: a 20-year follow up Cardiovasc Diabetol. 2013;12:155.
10. Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2010;56:50-103.
11. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC practice guidelines for the management of arterial hypertension. Blood Press. 2014;23:3-16.
12. Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarenco P, Bornstein N, et al. Mannheim carotid intima-media thickness and plaque consensus (2004–2006–2011). An update on behalf of the advisory board of the 3rd, 4th, and 5th watching the risk symposia, at the 13th, 15th, and 20th European Stroke Conferences, Mannheim, Germany, 2004, Brussels, Belgium, 2006, and Hamburg, Germany, 2011. Cerebrovasc Dis. 2012;34:290-6.
13. Goff DC, Jones DM, Bennett G, Coady S, Agostino RB, Gibbons R, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:2935-39.
14. Naqvi TZ, Lee MS. Carotid intima-media thickness and plaque in cardiovascular risk assessment. JACC Cardiovasc Imaging. 2014;7:1025-38.
15. Oygarden H. Carotid intima-media thickness and prediction of cardiovascular disease. J Am Heart Assoc. 2017;6:5313.
16. Touboul PJ, Vicaut E, Labreuche J, Acevedo M, Torres V, Martinez J, et al. Common carotid artery intima-media thickness: the Cardiovascular Risk Factor Multiple Evaluation in Latin America (CARMELA) study results. Cerebrovasc Dis. 2011;31:43-50.
17. Munckhof ICL, Jones H, Hopman MTE, Graaf J, Nyakayariru J, Dijk B, et al. Relation between age and carotid artery intima-medial thickness: a systematic review. Clin Cardiol. 2018;41:698-704.
18. Su TC, Chien KL, Jeng JS, Chen MF, Hsu HC, Torneg PL, et al. Age- and gender-associated determinants of carotid intima-media thickness: a community-based study. J Atheroscler Thromb. 2012;19:872-80.
19. Jiang F, Wang J, Zhang R, Chen M, Peng D, Sun X, et al. Effects of active and passive smoking on the development of cardiovascular disease as assessed by a carotid intima-media thickness examination in
patients with type 2 diabetes mellitus. Clin Exp Pharmacol Physiol. 2015;42:444-50.
20. Hansen K, Ostling G, Persson M, Nilsson PM, Melander O, Engstrom G, et al. The effect of smoking on carotid intima-media thickness progression rate and rate of lumen diameter reduction. Eur J Intern Med. 2016;28:74-9.
21. Itoh H, Kaneko H, Kiriyama H, Yoshida Y, Nakanishi K, Mizuno Y, et al. Relation between the updated blood pressure classification according to the American College of Cardiology/American Heart Association Guidelines and Carotid Intima-Media Thickness. Am J Cardiol. 2019;124:396-401.
22. Boloukat RR, Ramezankhani A, Hasheminia M, Tasdighi E, Azizi F, Hadaegh F. Impact of blood pressure, cholesterol, and glucose in the association between adiposity measures and coronary heart disease and stroke among Iranian population. Clin Nutr. 2018;37:2060-70.
23. Gao N, Zhang W, Zhang YZ, Yang Q, Chen SH. Carotid intima-media thickness in patients with subclinical hypothyroidism: a meta-analysis. Atherosclerosis. 2013;227:18-25.
24. Aziz M, Kandimalla Y, Machavarapu A, Saxena A, Das S, Younus A, et al. Effect of thyroxin treatment on carotid intima-media thickness (CIMT) reduction in patients with subclinical hypothyroidism (SCH): a meta-analysis of clinical trials. J Atheroscler Thromb. 2017;24:643-59.
25. Einarson TR, Hunchuck J, Hemels M. Relationship between blood glucose and carotid intima-media thickness: a meta-analysis. Cardiovasc Diabetol. 2010;9:37.
26. Cesana F, Giannattasio C, Nava S, Soriano F, Brambilla G, Baroni M, et al. Impact of blood glucose variability on carotid artery intima-media thickness and distensibility in type 1 diabetes mellitus. Blood Press. 2013;22:355-61.

Cite this article as: Gawali SM, Karandikar MS. The impact of insulin resistance, dyslipidemia and high sensitivity C-reactivity protein on carotid intima-media thickness in metabolic syndrome Int J Res Med Sci 2021;9:2347-53.